Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes
- PMID: 7398191
- DOI: 10.1038/clpt.1980.156
Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes
Abstract
A two-compartment physiologic pharmacokinetic model has been developed for 5-fluorouracil (5FU). This model, which incorporates saturable whole body clearance, satisfactorily predicts disappearance kinetics after an intravenous bolus and steady-state levels during constant intravenous infusions. A half-saturating concentration (KM) of 15 microM was determined by comparison of model simulations with literature data. Both hepatic and extrahepatic elimination can be inferred for 5FU, but the exact anatomic or compartmental location of the clearance cannot be determined from the available clinical data. The effect of venous and arterial plasma sampling is discussed. This model has been extended to include intraperitoneal and oral administration of 5FU by the addition of peritoneal fluid and liver compartments.
Similar articles
-
Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans.Cancer Res. 1981 May;41(5):1916-22. Cancer Res. 1981. PMID: 7214359
-
Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients.Cancer Res. 1986 Mar;46(3):1499-506. Cancer Res. 1986. PMID: 3943107
-
Comparison of 5-fluorouracil anabolite levels after intravenous bolus and continuous infusion.Cancer Chemother Pharmacol. 1994;34(4):293-6. doi: 10.1007/BF00686035. Cancer Chemother Pharmacol. 1994. PMID: 8033295
-
Clinical pharmacokinetics of fluorouracil and folinic acid.Semin Oncol. 1992 Apr;19(2 Suppl 3):82-92. Semin Oncol. 1992. PMID: 1557660 Review.
-
Fluorouracil: biochemistry and pharmacology.J Clin Oncol. 1988 Oct;6(10):1653-64. doi: 10.1200/JCO.1988.6.10.1653. J Clin Oncol. 1988. PMID: 3049954 Review.
Cited by
-
Bioavailability and feasibility of subcutaneous 5-fluorouracil.Br J Cancer. 1993 Sep;68(3):537-9. doi: 10.1038/bjc.1993.382. Br J Cancer. 1993. PMID: 8353044 Free PMC article.
-
Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe.Br J Clin Pharmacol. 2005 Dec;60(6):584-93. doi: 10.1111/j.1365-2125.2005.02472.x. Br J Clin Pharmacol. 2005. PMID: 16305582 Free PMC article.
-
Dose-dependent pharmacokinetics and cancer chemotherapy.Cancer Chemother Pharmacol. 1981;6(1):1-9. doi: 10.1007/BF00253003. Cancer Chemother Pharmacol. 1981. PMID: 7023712 Review.
-
Pharmacokinetic interactions of cimetidine 1987.Clin Pharmacokinet. 1987 May;12(5):321-66. doi: 10.2165/00003088-198712050-00002. Clin Pharmacokinet. 1987. PMID: 3301148 Review.
-
The influence of cimetidine on the pharmacokinetics of 5-fluorouracil.Br J Clin Pharmacol. 1984 Sep;18(3):421-30. doi: 10.1111/j.1365-2125.1984.tb02484.x. Br J Clin Pharmacol. 1984. PMID: 6487480 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources